TENEX

LOE Approaching

guanfacine hydrochloride

NDAORALTABLET
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3

Clinical Trials (3)

NCT01244490Phase 3Completed

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Started Jan 2011
338 enrolled
Attention Deficit Hyperactivity Disorder
NCT00997984Phase 3Completed

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Started Nov 2009
340 enrolled
Attention-Deficit/Hyperactivity Disorder
NCT00367835Phase 3Completed

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

Started Dec 2006
217 enrolled
ADHD
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.